41st Annual J.P. Morgan Healthcare Conference 2023

January 9, 2023



Forward-looking statements

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether the results of the FILLY, DERBY, and OAKS trials are sufficient to support regulatory submissions; whether a submission for approval of intravitreal pegcetacoplan for GA on the basis of the FILLY, DERBY and OAKS trials will be accepted by foreign regulatory agencies; whether intravitreal pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for GA when expected or at all; whether the company's clinical trials

will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether pegcetacoplan will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company's clinical trials will warrant regulatory submissions and whether pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for CAD, C3G, IC-MPGN, HSCT-TMA, ALS or any other indication when expected or at all; whether, if Apellis' products receive approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Apellis' Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2022 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forwardlooking statement, whether as a result of new information, future events or otherwise.

Apellis is revolutionizing complement science to deliver life-changing medicines

Targeting C3 for comprehensive control of complement



Advancing the first potential treatment for geographic atrophy (GA) U.S. PDUFA: Feb 26, 2023



SEMPAVELI® (pegcetacoplan) injection 1080 mg/20 mL solution



750+ employees globally



12 clinical and preclinical programs



2022 was a transformational year



Geographic Atrophy (GA): Ready to launch first-ever treatment

- ✓ Submitted NDA to U.S. FDA
- ✓ Submitted MAA to EMA
- U.S. commercial preparations complete; deployed ~100 fieldbased employees mid-2022
- Appointed leading retina specialist, Dr. Caroline Baumal as Chief Medical Officer (effective Jan 2023)



Paroxysmal Nocturnal Hemoglobinuria (PNH): Continued growth in demand

- ~\$65 million¹ in U.S. net product sales
- Submitted sNDA for PRINCE & 48-week PEGASUS data
- Submitted sNDA for EMPAVELI injector
- Completed >800 patient years of systemic dosing²



Pipeline: Leaders in complement

- Progressed late-stage clinical studies with partner Sobi
- Advanced early-stage pipeline across therapeutic areas
- ✓ Completed enrollment in Phase 2 ALS study

Apellis 1 Estimated 2022 EMPAVELI U.S. net product sales are unaudited, preliminary and based on management's estimate as of the date of this presentation and are subject to completion of the Company's financial closing procedures. 2. Includes 694 patients as of November 2022 from all subcutaneous pegcetacoplan clinical trials and post-marketing exposure of EMPAVELI.

Positioning Apellis for an extraordinary 2023



... with compassion and commitment to patients

GA is the leading cause of blindness worldwide





Normal vision



Vision with advanced GA

GAINS, a global patient survey, showed:

- Nearly 7 in 10 (68%) believe impact on independence and quality of life due to visual decline is worse than expected
- ~80% agree their vision was impacted faster than expected
- ~70% of patients find it hard to enjoy life as much as they had prior to GA diagnosis

Note: The Geographic Atrophy Insights Survey (GAINS) was conducted by The Harris Poll and was sponsored by Apellis.


Apellis 1 Boyer DS et al., Retina 2017

Pegcetacoplan positioned to be first-ever treatment for GA

In Phase 3 DERBY and OAKS studies at 24 months, pegcetacoplan showed:




Pegcetacoplan slowed GA progression with every-other-month and monthly dosing



GA= geographic atrophy; SE= standard error. Least square (LS) means estimated from a mixed-effects model for repeated measures (MMRM). The mITT population was used for the analysis, defined as all randomized patients who received at least 1 injection of pegcetacoplan or sham and have baseline and at least one post-baseline value of GA lesion area in the study eye.

Pegcetacoplan showed increasing treatment effects over time



P values for monthly and EOM, respectively, at 6 months: P=0.0058, P=0.0141; 12 months: P=0.0005, P=0.0012; 18 months: P<0.0001, P=0.0004; 24 months: P<0.0001, P<0.00

Percent reduction vs. pooled sham for Month 0 to Month 24 was estimated from a piecewise linear slope model with 6-month segments using the combined patient-level data, not a simple average of results, from the two studies. Point estimates for the Month 0 to Month 18 segments vary marginally from previously reported numbers due to the inclusion of the Month 20 to Month 24 data into the statistical model.

Pegcetacoplan slowed GA progression regardless of lesion location

All data represented are from DERBY and OAKS combined between months 18 and 24

	Subfoveal Lesions (foveal)	Non-subfoveal Lesions (extrafoveal)			
Monthly	34%	28%			
Every-Other-Month	28%	28%			



Pegcetacoplan demonstrated a favorable safety profile

All data represented are from DERBY and OAKS combined

EXUDATIONS1EOMMonthlySham Pooled0-12 months4.1%6.0%2.4%0-24 months
(cumulative)6.7%12.2%3.1%



Rates of endophthalmitis and intraocular inflammation generally in line with those reported in studies of other intravitreal therapies


...across 1,200 patients and nearly 12,000 injections

1. Exudations include all adverse events reported by the investigator as choroidal neovascularization (CNV) or neovascular AMD, whether or not there was reading center confirmation

Significant commercial opportunity with physicians eager to treat with pegcetacoplan



Built a best-in-class team highly experienced in the retina; fully deployed in August 2022



GA pre-launch activities underway ahead of February 26 PDUFA

MEDICAL





MOSAIC GA Patient & Caregiver Burden of Illness Study

>20 Scientific Education Programs

>100 Additional Platform
Presentations & Publications

COMMERCIAL



 >65 Physician Disease
 State Education (DSE)
 Campaign and Peer-to-Peer Meetings

Targeted media consistently reach 99% of retina specialists





Launched patient education efforts to support increased understanding of GA

PAYER

Engagement with National Payers representing ~80% of Medicare Advantage Lives



Distribution model and patient support services and resources finalized



...throughout 2022

...since September 2022

Pegcetacoplan positioned to be first-ever treatment for GA



Compelling product profile to address unmet need globally



>90% of surveyed retina specialists worldwide plan to use pegcetacoplan



Best-in-class field-based team deployed and ready for launch

Positioning Apellis for an extraordinary 2023



... with compassion and commitment to patients

Successful EMPAVELI launch, elevating the standard of care in PNH



As of December 31, 2022:

- ~\$65 million¹ in FY 2022 sales
- >260 HCPs with REMS certifications
- >230 start forms submitted
- ~10% of 2022 start forms were naïve patients
- 98% real world patient compliance rate

My hemoglobin is in the 12's as compared to the 8's. This is the first time in 6 years that I do not have to get bloodwork weekly or monthly ... I don't get repeat bloodwork for 6 months! EMPAVELI is life changing [for me].
EMPAVELI patient

Individual results may vary



Strengthening the EMPAVELI label and the patient experience in 2023



Supplemental NDA U.S. PDUFA Date Feb. 8, 2023

Enhancing our label with treatment-naive data from PRINCE and 48-week PEGASUS results



EMPAVELI Injector U.S. PDUFA Date March 15, 2023

Improving the patient experience and administration

Strong safety profile demonstrated through real-world experience



pegcetacoplan exposure¹

Zero reported cases of meningococcal infection¹

Thrombosis rate of 1.13 events per 100 patient-years²



1. Includes 694 patients as of November 2022 from all subcutaneous pegcetacoplan clinical trials and post-marketing exposure of EMPAVELI; 2 Includes patients from all PNH pegcetacoplan clinical trials and post-marketing exposure of EMPAVELI

Expanding potential indications




1. Based on moderate & severe patient population. CAD: Catenion using physician and literature consensus. Passweg et al, BMT. 2019, 38: 1575–1585 sus. C3G: ClearView Analysis using physician and literature consensus. 2. Based on sporadic only, patients seeking treatment, and non-monotherapy patients. ALS: ClearView Analysis based on physician interviews. 3. Based on TMA patients who display at least one high-risk feature. Phelan, R., Arora, M., Chen, M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020.. Jodele et al, Blood. 2014, 124(4): 645–653. Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan.

Positioning Apellis for an extraordinary 2023



... with compassion and commitment to patients

APL-2006: Developing potential best-in-class treatment for patients with wet AMD + GA; IND planned H1 2023



Next generation C3 siRNA + EMPAVELI




Reduce treatment frequency of EMPAVELI independent of indication



Silenced C3 expression >90% in pre-clinical studies




Advancing APL-1030 to establish proof of concept for C3 inhibition in neurological diseases



Advancing our Beam collaboration

Beam COLLABORATION:

 Research programs targeting eye, liver and brain advancing in preclinical studies





6 research programs over 5 years

AQ

Base editing technology to discover precision medicines for diseases of the eye, liver, and brain Focused on C3 and other complement targets




Modulating a complex biological system

Pipeline

	PRODUCT	DISEASE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	APPROVED
RARE DISEASE	EMPAVELI® (systemic pegcetacoplan)*	PNH					Marketed in the US
		IC-MPGN & C3G					
		ALS		Data expected mid-2023			
		CAD					
		HSCT-TMA		Phase 2 data expected H2 2023			
	siRNA + EMPAVELI**	Existing + new indications		IND in 1H'23			
OPHTHALMOLOGY	Intravitreal pegcetacoplan	GA			U.S.	PDUFA Feb. 26 '23	
	APL-2006	GA & Wet AMD		IND in 1H'23		1	
	Gene therapies	Wet AMD, Intermediate AMD & GA				1	
NEUROLOGY	APL-1030	Undisclosed				1	
	Brain shuttle	Undisclosed				1	
	Gene therapies	Undisclosed				1	
MULTIPLE THERAPEUTIC AREAS	Systemic pegcetacoplan	Control of host attack for gene therapies					
	Oral alternative pathway inhibitor	Mild C3G and other indications					
	Gene-edited therapies (Beam)	Undisclosed				I	

*Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan **Initial IND for siRNA



Positioning Apellis for an extraordinary 2023



... with compassion and commitment to patients

41st Annual J.P. Morgan Healthcare Conference 2023

January 9, 2023

